Arcapta Neohaler (indacaterol inhalation powder)
Arcapta Neohaler (indacaterol inhalation powder) is a maintenance treatment option for patients with chronic obstructive pulmonary disease (COPD). It is part of a class of drugs for treating COPD called long-acting beta2-adrenergic agonist (LABA). Arcapta Neohaler is used once each day, in controlling symptoms of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Arcapta Neohaler is not a rescue inhaler, which means that it should not be used for treating COPD symptoms that suddenly get worse, or for COPD flare-ups.
What are the ingredients in Arcapta Neohaler?
The active ingredient in Arcapta Neohaler is indacaterol.
How does Arcapta Neohaler work?
Patients using Arcapta Neohaler breathe in the medicine using a special inhaler once per day, at the same time every day. For each dose, patients insert a new capsule containing the medicine into the inhaler. The capsule should never be swallowed and it should only be used with the Arcapta Neohaler. The medicine starts to take effect within about 5 minutes, and it can help improve a person’s breathing for 24 hours until the next daily dose.
Arcapta Neohaler was designed to help you know if you have taken the entire dose correctly. It gives several signals that the inhaler is being used in the right way:
- The capsule clicks when it is put into the inhaler correctly
- The inhaler makes a whirring sound when the patient inhales
- The medicine leaves a faint taste in the mouth after inhaling
- The capsule is clear, so the patient can see if it is fully emptied at the end of the dose
Patients should not increase their daily dose of Arcapta Neohaler without consulting a healthcare provider.
What are the possible side effects of Arcapta Neohaler?
In clinical trials, the most common adverse reactions (occurring in >2% of people and more common than placebo) were cough, oropharyngeal pain, nasopharyngitis, headache and nausea. This is not an exhaustive list of all potential side effects of Arcapta Neohaler. Talk to your healthcare provider or pharmacist for further information.
Things to know about Arcapta Neohaler
Arcapta Neohaler has been approved for COPD only and is not indicated for the treatment of asthma. People with asthma who take long-acting beta2-adrenergic agonist (LABA) medicines, such as Arcapta Neohaler have an increased risk of death from asthma problems. It is not known if LABA medicines, such as indacaterol, increase the risk of death in people with COPD.
Arcapta Neohaler should not be used if you are allergic to indacaterol or any of the ingredients in Arcapta Neohaler
Tell your healthcare provider about all of your health conditions, including if you:
- Have heart problems
- Have high blood pressure
- Have seizures
- Have thyroid problems
- Have diabetes
- Are pregnant or plan to become pregnant
- Are breastfeeding or plan to breastfeed
- Are allergic to Arcapta Neohaler or any of its ingredients, any other medicines, or food products. Arcapta Neohaler contains lactose (milk sugar) and a small amount of milk proteins. It is possible that allergic reactions may happen in people who have a severe milk protein allergy
Arcapta Neohaler should be administered once daily every day at the same time of the day by the orally inhaled route only. If a dose is missed, the next dose should be taken as soon as it is remembered. Arcapta Neohaler should not be used more than one time every 24 hours.
Arcapta capsules can not be swallowed. The contents of Arcapta capsules are only for oral inhalation and should only be used with the Neohaler device.
For more information, read the full prescribing information of Arcapta Neohaler.
- Arcapta Neohaler [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; Revised March 2017./